Keros Therapeutics KROS
OrbiMed Private Investments VII (Shareholder) plans to sell 220,600 KROS shares, about $9.9M
- Form
- 144
- Filed
- Importance
- Routine
- Accession
- 0000947871-24-000687
- Approximate sale date: Aug 13, 2024
- Broker: Morgan Stanley Smith Barney
- Shares acquired by: IPO
All of OrbiMed Private Investments VII's insider filings, holdings and planned sales
Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):
- Sold 220,600 shares at $44.01 on Aug 13, 2024 ยท Form 4
Written from the Form 144 on EDGAR. Check the filing before you rely on it.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
- Theravance Biopharma TBPH public float $449M, Jun 30, 2025
- aTYR PHARMA ATYR public float $464M, Jun 30, 2025
- Arvinas ARVN public float $469M, Jun 30, 2025
- Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
